Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.
|
21996732 |
2012 |
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
|
31158500 |
2019 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
All of these results suggested that the lncRNA FER1L4 suppressed cell proliferation and metastasis by inhibiting the PI3K/Akt signaling pathway in lung cancer.
|
31115514 |
2019 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, previous studies have shown that Pg extracts decrease inflammation in lung cancer cell lines by inhibiting phosphatidylinositol-3,4,5-trisphosphate (PI3K)-dependent phosphorylation of AKT in vitro and inhibiting the activation of NF-kB in vivo.
|
22941571 |
2012 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
|
23728071 |
2013 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
This review aims to highlight the current knowledge about the ErbB network and the effect of NRG1 deregulation in lung cancer and their merger into the ErbB/PI3K-AKT axis modulation by current pharmacologic strategies.
|
28901268 |
2017 |
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We also evaluated epidermal growth factor receptor (EGFR) and PIK3CA mutations of captured CTC in a study of 4 lung cancer and 4 breast cancer patients.
|
26708016 |
2016 |
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Also, KPT-330 was effective even against NSCLC cells with a transforming mutation of either exon 20 of EGFR, TP53, phosphatase and tensin homologue, RAS or PIK3CA, suggesting the drug might be effective against a variety of lung cancers irrespective of their driver mutation.
|
24946002 |
2014 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, PI3K is a promising therapeutic target for lung cancer treatment.
|
29269744 |
2017 |
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations have been associated with poor prognosis in patients with colorectal or lung cancer.
|
23532889 |
2013 |
Malignant neoplasm of lung
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.
|
17992665 |
2008 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
The altered PI3K/mTOR pathway is implicated in lung cancer, but mTOR inhibitors have failed to demonstrate efficacy in advanced lung cancer.
|
25673697 |
2015 |
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genetic variants in PI3K/AKT pathway are associated with severe radiation pneumonitis in lung cancer patients treated with radiation therapy.
|
26645682 |
2016 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
The elevated calcium levels clinically observed in adenocarcinomas may explain calmodulin's involvement in recruiting and stimulating PI3Kα through interaction with its n/cSH2 domains as well as K-Ras4B; importantly, it also explains why K-Ras4B specifically is a key player in ductal carcinomas, such as pancreatic (PDAC), colorectal (CRC), and lung cancers.
|
26085527 |
2015 |
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Using the DNA extracted from formalin-fixed paraffin-embedded tumor samples, a MassArray-based Lung Cancer Mutations Screening Panel was performed to test for 179 individual mutations in 10 genes, including EGFR, KRAS, BRAF, ERBB2, JAK2, AKT1, AKT2, KIT, MET and PIK3CA, which have been implicated in lung carcinogenesis and/or considered as potential therapeutic targets.
|
23449277 |
2013 |
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Activation to a large extent of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and mutations in the p53 gene are involved in lung cancer therapeutic resistance.
|
20811722 |
2010 |
Malignant neoplasm of lung
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Compared with those in the control group, expression of PI3K and Akt in the lung cancer cells H1299 after EGCG treatment showed no significant differences (p>0.05), while expression levels of p-PI3K and p-Akt were significantly reduced (p<0.05).
|
30058690 |
2018 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Co-mutations in <i>TP53</i> and the <i>PI3K/AKT/mTOR</i> pathway confer additional resistance to anti-HER2 treatments in lung cancer.
|
31748336 |
2019 |
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer TCGA data validated these findings and unveiled overlap of FGFR1 mRNA positivity with KRAS and PIK3CA mutations.
|
24771645 |
2014 |
Malignant neoplasm of lung
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
With the expansion of our knowledge regarding the biology of KRAS-mutant lung cancers and the role of MEK and PI3K/mTOR inhibition, the face of targeted therapeutics for this genomic subset of patients is slowly beginning to change.
|
26667343 |
2016 |
Malignant neoplasm of lung
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
|
17409929 |
2006 |
Malignant neoplasm of lung
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.
|
29961813 |
2018 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibiting PI3K-AKt signaling pathway is involved in antitumor effects of ginsenoside Rg3 in lung cancer cell.
|
27930981 |
2017 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Further investigations showed that the PI3K/Akt signalling pathway and COX-2 are involved in endothelial tube formation under the stimulation of lung cancer cells.
|
28173828 |
2017 |
Malignant neoplasm of lung
|
0.600 |
Biomarker
|
disease |
BEFREE |
Long non-coding RNA OECC promotes cell proliferation and metastasis through the PI3K/Akt/mTOR signaling pathway in human lung cancer.
|
31452780 |
2019 |